Document Type

Article

Publication Date

10-2-2019

Publication Title

Oncology Letters

Publisher

Spandidos Publications

Volume

18

Issue

6

First page number:

6207

Last page number:

6213

Abstract

Glioma is one of the most common malignant tumor types of the central nervous system. It is necessary to identify biomarkers and novel therapeutic targets for glioma. The purpose of the present study was to distinguish lipid biomarkers with differential expression patterns in glioma tissues and normal brain tissues by matrix assisted laser desorption/ionization (MALDI)‑imaging and MALDI‑time of flight (TOF)‑mass spectrometry (MS). Additionally, identification of lipid biomarkers was performed to describe novel therapeutic targets for glioma treatment. A total of six tissues from three patients with glioma and three control patients with traumatic brain injury were analyzed using UltrafleXtreme MALDI‑TOF/TOF. The expression levels of 15 lipid peaks were higher in the TBT samples compared with in the GBT samples. The expression levels of another 16 lipid peaks were higher in the GBT samples compared with in the TBT samples. 14 peaks were identified as sphingomyelins using MS/MS. Additional results were also obtained from experiments using the glioma cell line U373‑MG. These results indicated that treatment with the drug desipramine (Desi) inhibited the accumulation of ceramide on the cell membranes of glioma U373‑MG cells. Treatment with Desi inhibited the activation of insulin‑like growth factor‑1 receptor and inhibited the activation of proteins in the PI3K/Akt signaling pathway.

Keywords

Glioma; Matrix assisted laser desorption/ionizationimaging; Lipid biomarkers; Sphingomyelin; PI3K/Akt signaling pathway

Disciplines

Oncology

File Format

pdf

File Size

396 KB

Language

English

Download

UNLV article access

Search your library

Included in

Oncology Commons

Share

COinS